Cartesian Therapeutics, Inc. has announced the upcoming initiation of its Phase 3 AURORA trial for Descartes-08, targeting myasthenia gravis, expected in the second quarter of 2025, following ...

FREDERICK, Md., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for ...

Cartesian Therapeutics (RNAC) announced updated efficacy and safety data from the Phase 2b trial of Descartes-08 in participants with generalized myasthenia gravis – MG – and provided details ...

Cartesian Therapeutics has a strong cash position after a $130 million equity ... More recently, in July 2024, the company presented positive topline data from Descartes-08's Phase 2b trials for ...

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price target remains the same with $45.00. Mitchell ...

Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial Dec. 03, 2024 6:00 ...